Sustiva

Country: European Union

Language: Latvian

Source: EMA (European Medicines Agency)

Active ingredient:

efavirenz

Available from:

Bristol-Myers Squibb Pharma EEIG

ATC code:

J05AG03

INN (International Name):

efavirenz

Therapeutic group:

Pretvīrusu līdzekļi sistēmiskai lietošanai

Therapeutic area:

HIV infekcijas

Therapeutic indications:

Sustiva indicēts pretvīrusu grupā, ārstējot cilvēkus ar imūndeficīta vīrusu-1 (HIV-1) inficētiem pieaugušajiem, pusaudžiem un bērniem no 3 gadu vecuma. Sustiva nav pietiekami pētīta pacientiem ar progresējošu HIV-slimību, proti, pacientiem ar CD4 skaitu < 50 šūnas/mm3, vai pēc neveiksmes proteāze-inhibitori (PI)-satur pulki. Lai gan pārrobežu pretestību efavirenz ar PIs nav stāstījuši, ka pašlaik ir nepietiekami dati par efektivitāti turpmākās izmantošanas PI-pamatojoties kombinēto terapiju, pēc neveiksmes pulki, kas satur Sustiva.

Product summary:

Revision: 48

Authorization status:

Autorizēts

Authorization date:

1999-05-28

Patient Information leaflet

                                1/1
ES NUMURS
PIEŠĶIRTAIS
NOSAUKUMS
STIPRUMS
ZĀĻU FORMA
IEVADĪŠANAS VEIDS
IEPAKOJUMS
IEPAKOJUMA
LIELUMS
EU/1/99/110/001
Sustiva
50 mg
Cietās kapsulas
Iekšķīgai lietošanai
pudele (ABPE)
30 kapsulas
EU/1/99/110/002
Sustiva
100 mg
Cietās kapsulas
Iekšķīgai lietošanai
pudele (ABPE)
30 kapsulas
EU/1/99/110/003
Sustiva
200 mg
Cietās kapsulas
Iekšķīgai lietošanai
pudele (ABPE)
90 kapsulas
EU/1/99/110/004
Sustiva
200 mg
Cietās kapsulas
Iekšķīgai lietošanai
pudele (alumīnija/PVH)
42 kapsulas
EU/1/99/110/008
Sustiva
600 mg
Apvalkotās tabletes
Iekšķīgai lietošanai
pudele (ABPE)
30 tabletes
EU/1/99/110/009
Sustiva
600 mg
Apvalkotās tabletes
Iekšķīgai lietošanai
blisters (alumīnija)
30 tabletes
EU/1/99/110/010
Sustiva
600 mg
Apvalkotās tabletes
Iekšķīgai lietošanai
blisters (alumīnija)
90 tabletes
Zāles vairs nav reğistrētas
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1/1
ES NUMURS
PIEŠĶIRTAIS
NOSAUKUMS
STIPRUMS
ZĀĻU FORMA
IEVADĪŠANAS VEIDS
IEPAKOJUMS
IEPAKOJUMA
LIELUMS
EU/1/99/110/001
Sustiva
50 mg
Cietās kapsulas
Iekšķīgai lietošanai
pudele (ABPE)
30 kapsulas
EU/1/99/110/002
Sustiva
100 mg
Cietās kapsulas
Iekšķīgai lietošanai
pudele (ABPE)
30 kapsulas
EU/1/99/110/003
Sustiva
200 mg
Cietās kapsulas
Iekšķīgai lietošanai
pudele (ABPE)
90 kapsulas
EU/1/99/110/004
Sustiva
200 mg
Cietās kapsulas
Iekšķīgai lietošanai
pudele (alumīnija/PVH)
42 kapsulas
EU/1/99/110/008
Sustiva
600 mg
Apvalkotās tabletes
Iekšķīgai lietošanai
pudele (ABPE)
30 tabletes
EU/1/99/110/009
Sustiva
600 mg
Apvalkotās tabletes
Iekšķīgai lietošanai
blisters (alumīnija)
30 tabletes
EU/1/99/110/010
Sustiva
600 mg
Apvalkotās tabletes
Iekšķīgai lietošanai
blisters (alumīnija)
90 tabletes
Zāles vairs nav reğistrētas
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 14-03-2024
Summary of Product characteristics Summary of Product characteristics Bulgarian 14-03-2024
Public Assessment Report Public Assessment Report Bulgarian 26-01-2018
Patient Information leaflet Patient Information leaflet Spanish 14-03-2024
Public Assessment Report Public Assessment Report Spanish 26-01-2018
Patient Information leaflet Patient Information leaflet Czech 14-03-2024
Public Assessment Report Public Assessment Report Czech 26-01-2018
Patient Information leaflet Patient Information leaflet Danish 14-03-2024
Public Assessment Report Public Assessment Report Danish 26-01-2018
Patient Information leaflet Patient Information leaflet German 14-03-2024
Public Assessment Report Public Assessment Report German 26-01-2018
Patient Information leaflet Patient Information leaflet Estonian 14-03-2024
Public Assessment Report Public Assessment Report Estonian 26-01-2018
Patient Information leaflet Patient Information leaflet Greek 14-03-2024
Public Assessment Report Public Assessment Report Greek 26-01-2018
Patient Information leaflet Patient Information leaflet English 14-03-2024
Public Assessment Report Public Assessment Report English 26-01-2018
Patient Information leaflet Patient Information leaflet French 14-03-2024
Public Assessment Report Public Assessment Report French 26-01-2018
Patient Information leaflet Patient Information leaflet Italian 14-03-2024
Public Assessment Report Public Assessment Report Italian 26-01-2018
Patient Information leaflet Patient Information leaflet Lithuanian 14-03-2024
Summary of Product characteristics Summary of Product characteristics Lithuanian 14-03-2024
Public Assessment Report Public Assessment Report Lithuanian 26-01-2018
Patient Information leaflet Patient Information leaflet Hungarian 14-03-2024
Summary of Product characteristics Summary of Product characteristics Hungarian 14-03-2024
Public Assessment Report Public Assessment Report Hungarian 26-01-2018
Patient Information leaflet Patient Information leaflet Maltese 14-03-2024
Public Assessment Report Public Assessment Report Maltese 26-01-2018
Patient Information leaflet Patient Information leaflet Dutch 14-03-2024
Public Assessment Report Public Assessment Report Dutch 26-01-2018
Patient Information leaflet Patient Information leaflet Polish 14-03-2024
Public Assessment Report Public Assessment Report Polish 26-01-2018
Patient Information leaflet Patient Information leaflet Portuguese 14-03-2024
Summary of Product characteristics Summary of Product characteristics Portuguese 14-03-2024
Public Assessment Report Public Assessment Report Portuguese 26-01-2018
Patient Information leaflet Patient Information leaflet Romanian 14-03-2024
Public Assessment Report Public Assessment Report Romanian 26-01-2018
Patient Information leaflet Patient Information leaflet Slovak 14-03-2024
Public Assessment Report Public Assessment Report Slovak 26-01-2018
Patient Information leaflet Patient Information leaflet Slovenian 14-03-2024
Summary of Product characteristics Summary of Product characteristics Slovenian 14-03-2024
Public Assessment Report Public Assessment Report Slovenian 26-01-2018
Patient Information leaflet Patient Information leaflet Finnish 14-03-2024
Public Assessment Report Public Assessment Report Finnish 26-01-2018
Patient Information leaflet Patient Information leaflet Swedish 14-03-2024
Public Assessment Report Public Assessment Report Swedish 26-01-2018
Patient Information leaflet Patient Information leaflet Norwegian 14-03-2024
Summary of Product characteristics Summary of Product characteristics Norwegian 14-03-2024
Patient Information leaflet Patient Information leaflet Icelandic 14-03-2024
Summary of Product characteristics Summary of Product characteristics Icelandic 14-03-2024
Patient Information leaflet Patient Information leaflet Croatian 14-03-2024
Public Assessment Report Public Assessment Report Croatian 26-01-2018

Search alerts related to this product

View documents history